Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity

Conclusion: Children with a history of type 1 ROP treated with ranibizumab did not show a myopic shift but did show abnormal retinal morphology and the poorest BCVA among all groups. We suggest that pediatric ophthalmologists should always pay attention to visual development in patients with ROP with a history of intravitreal ranibizumab.What is Known:• Anti-VEGF is efficiently and widely used in the treatment of type 1 retinopathy of prematurity (ROP), and different anti-VEGF agents are associated with different prevalence of myopia.• Patients with ROP who receive treatment such as laser therapy or cryotherapy have abnormal macular development and retinal nerve fiber layer (RNFL) thickness.What is New:• Children with a history of ROP treated with intravitreal ranibizumab did not show a myopic shift but did show poor BCVA at 4–6 years of age.• Abnormal macular morphology and lower peripapillary RNFL thickness were found in these children.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research